Large genetic study links telomere-related polygenic risk to distinct idiopathic pulmonary fibrosis subgroups, improving ...
Hosted on MSN
Pulmonary fibrosis: Nerandomilast inhibits phosphodiesterase 4B, may treat multiple forms of disease
A new drug for pulmonary fibrosis has reduced disease progression by more than 50% over a 52-week treatment in two clinical trials. Pulmonary fibrosis is a very serious disease, with a life prognosis ...
A study from China has reported that Cordyceps sinensis (CS), a traditional Chinese medicinal fungus, can ameliorate idiopathic pulmonary fibrosis (IPF) in mice by inhibiting mitochondrion-mediated ...
The combination of antifibrotic therapy and pulmonary vasodilator therapy improved transplant-free survival but had no significant impact on exercise capacity in pulmonary fibrosis and pulmonary ...
AI-based imaging tools have shown potential in detecting treatment responses in IPF, supporting the use of ENV-101 and AI imaging as trial endpoints. The forced oscillation technique (FOT) may enhance ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Jeffrey J. Swigris ...
Researchers have found a potential new way to slow the progression of lung fibrosis and other fibrotic diseases by inhibiting the expression or function of Piezo2, a receptor that senses mechanical ...
In a phase 3 study, nerandomilast administered at 18 mg or 9 mg twice daily slowed the progression of pulmonary fibrosis in adults with progressive pulmonary fibrosis. In a previous study, ...
If you have scarring in your lungs, you may have been diagnosed with pulmonary fibrosis. When the reason for this scarring is unknown, your condition is called idiopathic pulmonary fibrosis (IPF). You ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results